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We retrospectively review outcomes of applying boron neutron capture therapy (BNCT) to unresectable
advanced or recurrent head and neck cancers. Patients who were treated with BNCT for either local recurrent
or newly diagnosed unresectable head or neck cancers between December 2001 and September 2007 were
included. Clinicopathological characteristics and clinical outcomes were retrieved from hospital records.
Either a combination of borocaptate sodium and boronophenylalanine (BPA) or BPA alone were used as
boron compounds. In all the treatment cases, the dose constraint was set to deliver a dose <10–12 Gy-eq to the
skin or oral mucosa. There was a patient cohort of 62, with a median follow-up of 18.7 months (range,
0.7–40.8). A total of 87 BNCT procedures were performed. The overall response rate was 58% within
6 months after BNCT. The median survival time was 10.1 months from the time of BNCT. The 1- and 2-year
overall survival (OS) rates were 43.1% and 24.2%, respectively. The major acute Grade 3 or 4 toxicities were
hyperamylasemia (38.6%), fatigue (6.5%), mucositis/stomatitis (9.7%) and pain (9.7%), all of which were
manageable. Three patients died of treatment-related toxicity. Three patients experienced carotid artery
hemorrhage, two of whom had coexistent infection of the carotid artery. This study confirmed the feasibility
of our dose-estimation method and that controlled trials are warranted.
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INTRODUCTION
The incidence rate in Japan of head and neck cancer during
2008 was 16.3/100 000 population, and approximately 7800
cases died during 2011. Both the incidence and mortality rates
of head and neck cancer are increasing. Aggressive and com-
bined local treatment including surgery and chemoradiation
has been applied to advanced head and neck cancer, because
the prognosis for patients with recurrent disease is generally
poor. Unfortunately, the rate of local recurrence has been
reported at 20–57% following aggressive local treatment.
For unresectable recurrent head and neck cancer, chemo-
therapy alone has been considered standard treatment.
However, the therapeutic effect of chemotherapy is limited to
palliative settings. Reirradiation with or without chemother-
apy has been investigated since the 1990s as curative treat-
ment for unresectable advanced or recurrent head and neck
cancer. Single or multicenter studies of combined treatment
with reirradiation and chemotherapy have demonstrated a
small number of patients with long-term survival [1, 2].
Although substantial morbidity related to reirradiation has
been reported in these studies, reirradiation with or without
chemotherapy has the potential to cure unresectable recurrent
head and neck cancer.
The rationale for application of reirradiation with boron
neutron capture therapy (BNCT) for recurrent head and neck
cancer is based on the unique property of BNCT, which can
deposit a large dose gradient between the tumor and sur-
rounding normal tissues. BNCT is based on the following
nuclear reaction. Nonradioactive isotope 10B atoms that
absorb low-energy (<0.5 eV) neutrons (thermal neutrons)
disintegrate into an alpha (4He) particle and a recoiled
lithium nucleus (7Li). These particles deposit high energy
along their very short path (<10 µm) [3]. Thus, only malig-
nant cells with 10B are destroyed following thermal neutron
irradiation. Theoretically, any normal cells abutting the
cancer cells are spared from high linear energy transfer
(LET) irradiation by 4He and 7Li particles.
In 2001, a patient with recurrent parotid gland tumor after
standard therapies including surgery, radiotherapy and chemo-
therapy was referred to the Kyoto University Research Reactor
Institute (KURRI) from Osaka University, Graduate School of
Dentistry. The patient was treated with BNCT at KURRI,
which was the first such attempt worldwide [4]. In the first
case, locoregional control of the patient was achieved for
7 years until the patient died of intercurrent disease. This
promising initial result prompted clinical trials of BNCT for
head and neck cancer in Japan and Finland, and several case
reports of BNCT for recurrent head and neck tumors have
been published by our research group [5, 6].
To investigate the efficacy and safety of applying BNCT
to head and neck cancers, we conducted an outcomes study




Patients who were treated with BNCT at KURRI for either
locoregionally recurrent or newly diagnosed head or neck
cancers between December 2001 and September 2007 were
identified in the hospital’s medical records. Clinicopathological
characteristics and clinical outcomes of the patients were
retrieved from these records. This study was performed accord-
ing to Ethical Guidelines for Epidemiological Research by the
Japanese Government. Informed consent was obtained accord-
ing to the guidelines. The study protocol was approved by the
Ethical Review Board of each medical institute.
Overview of BNCT for head and neck tumors
Boronophenylalanine (BPA) and borocaptate sodium (BSH),
which have been employed in clinical BNCT trials for malig-
nant glioma or melanoma, were used in the present study
of BNCT for head and neck cancers. All the patients
showed good accumulation of BPA in the tumor in an
18F-BPA-positron emission tomography (PET) study before
BNCT. In 72 cases, BPA in fructose solution (BPA-f) was
intravenously administered at a dose of 250 or 500 mg/kg. A
further 15 cases received both BSH (5 g/body) dissolved in
50% physiological saline solution and BPA-f (250 mg/kg)
intravenously. Two different treatment schedules were adopted
in the cases treated with BPA alone. Until May 2004, BPA
was administered at a dose of 250 or 500 mg/kg in 1–2 h, fol-
lowed by epithermal neutron irradiation within 15 min after
finishing administration of the BPA-f solution. From June
2004, BPA was administered at a dose of 500 mg/kg in 3 h at
a rate of 200 mg/kg/h for the initial 2 h, and at the reduced
speed of 100 mg/kg/h for the remaining 1 h. Epithermal
neutron irradiation was carried out during the final 1 h during
infusion of BPA at a speed of 100 mg/kg/h. In cases adminis-
tered both BSH and BPA, the epithermal neutron irradiation
was started 12 h and 1 h after finishing of administration of
BSH and BPA, respectively. The irradiation time was deter-
mined so that the maximum dose to the surrounding normal
tissues (oral mucosa in the majority of the cases and skin in
the remainder) would be <10–12 Gy-eq.
Radiation treatment planning
Details of the procedures for radiation treatment planning with
a Simulation Environment for Radiotherapy Applications
(SERA) system and the Japan Atomic Energy Research
Institute’s Computational Dosimetry System, which are cur-
rently available BNCT treatment-planning systems, have been
published [7].
SERA has been described in our previous report on a
treatment-planning study of BNCT for multiple liver tumors
[8]. We describe the procedure briefly here. First, the com-
puted tomography (CT) images of each patient with head
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and neck tumors were inputted to the SERA system. On each
slice of the CT image, the volume for the gross tumor
volume and surrounding normal tissues including muscle,
adipose tissue, skin and mucosa, bone and air (e.g. oral
cavity and airway) were delineated. The behavior of thermal
neutrons in the body is heavily affected by the proton density
in the tissues; therefore, bone and air should be depicted
separately.
Biological effects of boron compounds depend on their
microdistribution in the tissues and the morphological char-
acteristics of the target cells. Therefore, compound biological
effectiveness (CBE) factors were used as alternative relative
biological effectiveness (RBE) factors [3]. BNCT consists of
mixed radiation fields, with three different types of radiation
as follows: (i) low-LET γ rays, resulting primarily from the
capture of thermal neutrons by normal tissue hydrogen
atoms [1H(n,γ)2H] and contaminating γ-rays from the
neutron beam port (bismuth-surface), the collimator and the
irradiation room wall; (ii) high-LET protons, produced by
the scattering of fast neutrons [1H(n,n)1H] and from the
capture of thermal neutrons by nitrogen atoms [14N(n,p)14C];
and (iii) high-LET, heavier-charged particles consisting of
4He nuclei and 7Li ions, released as products of thermal
neutron capture reactions (BNCR) with 10B [10B(n,α)7Li].
The doses by epithermal neutron beam in the absence of 10B
comprise the low-LET γ-ray dose plus the high-LET proton
dose as described above. The CBE factor was calculated
using the following equation.
CBE factor ¼ ðDXray  Dbeam  RBEbeamÞ=DBNCR;
where DX-ray, Dbeam and DBNCR are the doses of the reference
X-ray, the epithermal neutron beam, and the 4He nuclei and
7Li particles derived from the 10B(n,α)7Li reaction required
for equal biological effect; RBEbeam is the RBE for the
epithermal neutron beam alone in the absence of 10B. The
RBE or CBE factors for the tumor and normal tissues are
summarized in Table 1.
The parameters and values required in the calculation with
SERA include the 10B concentrations in the tumor or normal
tissues, the thermal neutron fluence, the nitrogen composition
of the tissues, the RBE of each component of the beam, and
the CBE factors of the boron compound. The accumulation of
BPA in the tumor and normal tissue was imaged and quantified
as a tumor/blood ratio (T/B ratio) by an 18F-BPA positron
emission tomography (PET) study before BNCT, as previously
described [4]. In the 18F-BPA PET study performed before
BNCT, 18F-BPA was injected through the same route as for
BNCT on the day of treatment. 10B concentrations in the tumor
during irradiation were estimated by multiplying the T/B ratio
by 10B concentrations in the normal tissue during irradiation.
In the present study, 10B concentrations in the normal tissue
were assumed to be equal to blood 10B concentrations during
irradiation. 10B concentrations in the blood during irradiation
were calculated as the mean 10B concentrations in the blood
sampled just before and just after the irradiation, because 10B
concentrations in blood should have been decreased after the
finish of injection of BPA.
Thermal neutron fluence was measured by radioactivation
of gold wires (0.25 mm in diameter and 1.0 cm long) placed
on the skin surface of the lesion. The SERA system was run
for the dose calculation after all the parameters were entered.
The dose–volume histogram (DVH) parameters, as well as
the maximum, mean and minimum doses given to the gross
tumor volume, were evaluated for each case.
Evaluation of efficacy and safety
Tumor response evaluations were performed with either CT
or magnetic resonance imaging (MRI) performed within 6
months after BNCT using the RECIST (Response Evaluation
Criteria in Solid Tumors) criteria version 1.0. Overall survival
(OS) time was calculated from the initiation of BNCT to the
date of any cause of death or last confirmed day of survival,
whichever occurred first. Progression-free survival (PFS) time
was calculated from the initiation of BNCT to the progression
or death from any cause, whichever occurred first. Adverse
events were graded according to the Common Terminology
Criteria for Adverse Events v3.0 (CTCAE v3.0). Following
BNCT, 40% of patients received other therapies; therefore,
adverse effects that occurred within 1 month after BNCT were
analyzed.
Table 1. RBE and CBE factors used for conversion of physical dose (Gy) to photon-equivalent dose (Gy-eq)
BNCT dose components Tumor Skin Oral mucosa
10B (n, α) 7Li 3.8 (CBE for BPA) 2.5 (CBE for BPA) 4.9 (CBE for BPA)
2.5 (CBE for BSH) 0.8 (CBE for BSH) 0.3 (CBE for BSH)
14N (n, p) 14C 3.0 3.0 3.0
Fast neutron 3.0 3.0 3.0
gamma-ray 1.0 1.0 1.0
BNCT = boron neutron capture therapy, RBE = relative biological effectiveness, CBE = compound biological effectiveness,
BPA = boronophenylalanine, BSH = borocaptate sodium.
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Data management and statistics
Data collection, management and analyses were conducted
by the independent datacenter in the Translational Research
Center, Kyoto University Hospital. OS and PFS were ana-
lyzed using the Kaplan–Meier method. All statistical ana-
lyses were performed using SAS version 9.1.3 (SAS Institute
Inc., Cary, NC, USA).
RESULTS
Patient characteristics
Patient characteristics are detailed in Table 2. A total of
62 patients were treated with BNCT between December
2001 and September 2007. All the patients in this study had
unresectable advanced or recurrent head and neck cancers.
Of the 62, 13 (21%) patients had newly diagnosed unresect-
able tumors, and 49 (79%) patients had recurrent tumors.
In the 49 patients, 41 (84%), 36 (73%) and 39 (80%) had
undergone previous surgical resection, radiotherapy and
chemotherapy, respectively. The majority of treatment sites
were oral cavity, nasal cavity, paranasal sinuses, or neck.
Patients with squamous cell carcinoma, adenocarcinoma and
malignant melanoma numbered 33 (53%), 20 (32%) and 11
(18%), respectively.
Treatment characteristics
Treatment characteristics are summarized in Table 3. Of the
62 patients, 42 received BNCT once, 17 received it twice,
two received it three times, and one received it five times.
A total of 87 BNCT procedures were performed on the
62 patients. Both BSH and BPA-f were used in 13 treat-
ments, and BPA-f alone was used in 72. In the 72 treatments
with BPA-f alone, a dose of 250 mg/kg was used in five
treatments and 500 mg/kg in 67.
The median tumor diameter and depth from the skin was
48 mm (range, 10–135 mm) and 50 mm (range, 0–100 mm),









Median age (range) 61 (31–85)
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Table 3. Treatment characteristics
Total BNCT treatments 87
Once 42 cases
Twice 17 cases
Three times 2 cases
Five times 1 case
Boron compound





Maximum tumor diameter (mm) 48 mm (10–135)
Maximum tumor depth (mm) 50 mm (0–100)
T/B ratio 3.0 (1.7–6.1)
Minimum tumor dose (Gy-eq) 17.9 (4.0–44.5)
Maximum skin dose (Gy-eq) 6.9 (2.7–30.3)
Maximum oral mucus dose (Gy-eq) 10.9 (4.4–17.2)
T/B ratio = tumor/blood ratio.
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respectively. The median T/B ratio assessed before BNCT
by the 18F-BPA PET study was 3.0 (range, 1.7–6.1). The
median minimum tumor dose was 17.9 Gy-eq (range, 4.0–
44.5 Gy-eq). The median maximum skin and oral mucosa
doses were 6.9 Gy-eq (range, 2.7–30.3 Gy-eq) and 10.9
(range, 4.4–17.2 Gy-eq), respectively.
Treatment results
Survival data were available for 53 patients. The median
follow-up was 18.7 months (range, 0.7–40.8 months).
Response to BNCT was assessed using imaging studies,
CT or MRI, performed within 6 months after BNCT. In 57
patients, the response data were valid. Of the 57, 16 patients
(28%) showed a complete response (CR), and 17 patients
(30%) had a partial response (PR). The overall response rate
(CR + PR) for all the patients, the 13 patients with newly
diagnosed unrespectable tumors and the 46 with recurrent
tumors was 58%, 39% and 61% within 6 months after
BNCT, respectively.
The median survival time (MST) was 10.1 months from
the time of BNCT, and the 1- and 2-year OS rates were 43%
and 24%, respectively (Fig. 1). The 1-year OS rate for the
10 patients with newly diagnosed unresectable tumors
and the 43 with recurrent tumors was 58% and 41%, respect-
ively (Fig. 1). In the patients with recurrent tumors, the
MST, median PFS time and 1-year PFS rate were 9.7
months, 5.1 months and 5%, respectively. In the analysis of
the patients with recurrent tumors, the 1-year OS rates for
squamous cell carcinoma (n = 29), malignant melanoma
(n = 6), and adenocarcinoma (n = 6) were 26%, 60% and
100%, respectively.
Toxicity
The acute adverse events occurring within 1 month after
BNCT were analyzed because 43% of the patients underwent
other therapies following BNCT. BNCT-related acute toxici-
ties were graded according to the CTCAE v3.0 and are listed
in Table 4. The major acute Grade 3 or 4 toxicities were
hyperamylasemia (38.6%), fatigue (6.5%), mucositis/stoma-
titis (9.7%) and pain (9.7%), all of which were manageable.
One of these toxicities, hyperamylasemia, was presumably
the result of irradiation of the salivary gland. This was an
inevitable adverse event but did not lead to any serious situ-
ation. Three patients experienced carotid artery hemorrhage,
and two died of rupture of an infected carotid artery. In add-
ition, the carotid arteries that ruptured were invaded by recur-
rent tumor and reirradiated with BNCT. One patient died
from malnutrition secondary to poor feeding. Details of
these four patients are presented in Table 5.
DISCUSSION
The purpose of this outcomes study was to investigate the
safety and efficacy of BNCT for advanced or recurrent head
and neck cancers. With regard to safety, the incidence of
high-grade (≥3) toxicity, except for hyperamylasemia, was
<10%. The incidence of Grade 3 and 4 acute dermatitis and
mucositis/stomatitis was 3.2% and 9.7%, respectively, which
was acceptably low considering that 79% patients with
recurrent tumor received reirradiation with BNCT. A dose
<10–12 Gy-eq for skin and oral mucosa was set as the dose
constraint; therefore, the median maximum doses delivered
Fig. 1. OS for all patients, those with a newly diagnosed tumor,
and those with a recurrent tumor.
Table 4. Acute adverse events at 1 month after BNCT
Adverse event Grade 3 Grade 4 % Grade 3/4
Anemia 0 1 1.6
Leucopenia 0 1 1.6
Thrombocytopenia 0 1 1.6
Hyperamylasemia 10 7 27.4
Renal toxicity 1 0 1.6







Fatigue 4 0 6.5
Radiation dermatitis 1 1 3.2
Ulceration (skin) 2 0 3.2
Xerostomia 1 0 1.6
Dysphagia 2 0 3.2
Mucositis 4 2 9.7
Keratitis 1 0 1.6
Pain 6 0 9.7
Dyspnea 3 0 4.8
Edema, larynx 2 0 3.2
Vocal changes 1 0 1.6
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to the skin and mucosa were estimated at 6.9 and 10.9
Gy-eq, respectively (Table 2). The dose calculation for
BNCT has more complexity and uncertainty compared with
other radiotherapy modalities. For example, the CBE factor
(photon-equivalent convergent coefficient) for skin is differ-
ent from that for oral mucosa, and the 10B concentration in
normal tissues is assumed to be equal to that in the blood.
Since, in this retrospective study, acute adverse effect was
evaluated once at 1 month after BNCT, further prospective
trials are needed for evaluation of late adverse effects. With
regard to dose evaluation, acceptable acute skin and mucosa
toxicity revealed in this present study suggests that the para-
meters and assumptions used in the BNCT dose calculation
were appropriate and feasible.
One serious adverse reaction in the treatment of head and
neck cancer with radiotherapy was carotid hemorrhage. This
event occurred in three patients in the present study, and two
of them died. The incidence rate of carotid hemorrhage (4.8%)
observed in this study was comparable with that reported in
the literature [9]. In all three cases, the ruptured carotid artery
was invaded by the surrounding advanced tumor. Although
BNCT can deposit a large dose gradient between the tumor
and surrounding normal tissues, BNCT should be applied cau-
tiously to such cases. If a carotid artery is surrounded by the
tumor, angiography for evaluating the wall of the carotid
artery should be performed. Irregularity of the wall suggests
the invasion of the carotid artery by the surrounding tumor.
BNCT should not be indicated in such cases.
The selected studies of concurrent reirradiation and
chemotherapy for recurrent head and neck cancer are sum-
marized in Table 6 [10–18]. According to these reports, con-
current chemo-reirradiation trials yielded an overall response
rate ranging from 41–80%, MST 8.5–14 months, 1-year OS
37–56%, and 2-year OS 15–35%. The results in this study
were difficult to compare with those in trials of chemo-
irradiation as a result of the loss of survival data for 9 patients
(15%), the heterogeneity of the patients and tumors, includ-
ing different tumor status (recurrent or newly diagnosed),
varying histology (squamous cell carcinoma, melanoma,
adenocarcinoma, and others), and different chemotherapy
after BNCT. However, the overall response rate and MST,
and 1-year OS for recurrent head and neck cancer in the
present study were 61%, 9.7 months and 41%, which are
promising results and warrant a further prospective clinical
trial of BNCT for recurrent head and neck cancer.
Recently, intensity-modulated radiotherapy (IMRT) and
stereotactic radiotherapy (SRT), as forms of reirradiation,
have been applied to the treatment of recurrent, previously
irradiated head and neck cancer. These techniques can
deliver a definitive dose to the recurrent tumor while sparing
neighboring normal tissues. Sulman et al. have reported the
results of a study in which all 78 patients were treated with
IMRT. The 2-year OS and local control rates were 58% and
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experience of SRT using CyberKnife for recurrent head and
neck cancer [20]. The response rate (CR + PR) was 80%, and
the 1- and 2-year OS rates were 52.1% and 30.9%, respect-
ively. In both studies, local control and survival data were su-
perior to those obtained with concurrent chemo-reirradiation
using conventional irradiation techniques, and
treatment-related morbidity was less common. Therefore,
reirradiation using these new techniques has the potential to
become standard therapy for locally recurrent head and neck
cancer.
In these circumstances of remarkable progress in radio-
therapy techniques, we have investigated the possibility that
BNCT can be applied to locally advanced or recurrent head
and neck cancer. The drawback of BNCT is that deep-seated
tumors cannot receive an sufficient irradiation dosethe owing
to poor penetration of thermal neutrons in the body. In the
present study, the maximum tumor depth ranged from
0–100 mm, and the minimum tumor dose ranged from
4.0–44.5 Gy-eq, which indicates that, in many cases, the
doses delivered to the deep-seated tumors were insufficient
to control the tumors. In addition, we calculated the tumor
dose on the assumption that BPA distributed homogeneously
in the tumor. The region with insufficient distribution of
BPA may receive much a lower dose compared with the
calculated minimum tumor dose. Therefore, in future clinical
trials, BNCT for head and neck cancer should be limited
to shallow-seated tumors, and the dose constraint should
be set to the dose delivered to normal mucosa or skin in
which BPA is assumed to distribute more homogeneously
compared with the tumor.
All the patients with adenocarcinoma survived, although
the number was very small. 4He particles and 7Li nuclei ir-
radiating the tumor in BNCT are high-LET heavy ion parti-
cles; therefore, BNCT is theoretically expected to control
radioresistant tumors such as adenocarcinoma. In addition,
adenocarcinoma in the head and neck region has a tendency
Table 6: Treatment outcomes of chemo-reirradiation for recurrent head and neck cancer
Authors n Radiotherapy Chemotherapy Response rate Survival
De Crevoisier et al. [10] 169 Median 60 Gy HU, 5-FU or MMC, 5-FU, CDDP CR: 37% 2-year OS: 21%
PR: 11%
Langer et al. [11] 99 60 Gy: 1.5 Gy b.i.d. CDDP, paclitaxel Not mentioned MST: 12.1 months
1-year OS: 50.2%
2-year OS: 25.9%
Spencer et al. [12] 52 Median 50 Gy 5-FU, HU CR: 30% MST: 9.4 months
PR: 22% 1-year OS: 39%
2-year OS: 15%
Spencer et al. [13] 79 60 Gy: 1.5 Gy b.i.d. 5-FU, HU Not mentioned MST: 8.5 months
1-year OS: 40.5%
2-year OS: 15.2%
Schaefer et al. [14] 32 Median 50 Gy 5-FU, HU CR: 19% MST: 9.0 months
PR: 22% 1-year OS: 39%
Weppelmann et al. [15] 21 40 Gy (n = 11) 5FU, HU CR: 43% 1-year OS: 56%
48 Gy (n = 10) PR: 29%
Kramer et al. [16] 34 60 Gy: 1.5 Gy b.i.d. CDDP, paclitaxel Not mentioned MST: 12.4 months
1-year OS: 50%
2-year OS: 35%
Hehr et al. [17] 27 40 Gy CDDP, dicotaxel CR: 36% MST: 10 months
PR: 44% 1-year OS: 37%
3-year OS: 18%
Cohen et al. [18] 25 72 Gy CDDP, tirapazamine CR: 28% MST: 14 months
PR: 20% 1-year OS: 56%
2-year OS: 27%
HU = hydroxyuria, 5-FU = 5-fluorouracil, CR = complete response, PR = partial response, OS = overall survival, b.i.d. = twice daily,
CDDP = cisplatine, MST =median survival time.
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for microscopic perineural invasion. In IMRT or SRT for re-
current head and neck cancer, the planning target volume
(PTV) margin is commonly very small (0–5 mm); therefore,
microscopic perineural invasion has the risk of extending out
of the PTV. In contrast, in BNCT, neutron beams irradiate
the tumor with a wide margin >5 cm, using a 10–15-cm
diameter round collimator. Therefore, BNCT has the poten-
tial to eradicate cancer cells that microscopically invade the
tumor and exist in the perineural portion outside the gross
tumor. Adenocarcinoma is a good indication for BNCT,
especially when at a shallow location.
CONCLUSION
In conclusion, this study of BNCT for advanced or recurrent
tumors revealed two important findings. First, we confirmed
the feasibility of our dose-evaluation method with regard to
skin and oral mucosa. Second BNCT-related morbidity and
mortality were acceptably low. This study warrants the clin-
ical trial in the planning stage with full consideration of the
eligibility criteria, especially in regard to the maximum
tumor depth and histology.
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